Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
==== Clinical trials ==== In terms of antimicrobial performance, studies report that the peptides found in DBHA can selectively kill microorganisms without significant toxicity to host cells. This is attributed to the presence of free protonated amines in G3KPCA, which interact with and disrupt negatively charged bacterial membranes, contributing to bactericidal activity. In vitro compatibility tests using mouse NIH-3T3 fibroblasts showed that DBHA is non-cytotoxic under the tested condition. DBHA has also been tested in more realistic conditions, including bleeding environments. When applied to porcine skin covered in blood, only minor differences were observed between wet and dry adhesion performance. It was also tested on tissues such as the stomach, heart, artery, and liver, where adhesion forces were measured. In rat incision models, DBHA was used in wound closure studies where closure was observed after seven days, in comparison to conventional sutures and commercial adhesives. Additional testing showed that after 24 hours in an adhesive conditioned medium, human dermal fibroblasts remained viable, indicating biocompatibility.
Optical: To improve visual acuity by replacing the opaque or distorted host tissue by clear healthy donor tissue. The most common indication in this category is pseudophakic bullous keratopathy, followed by keratoconus, corneal degeneration, keratoglobus and dystrophy, as well as scarring due to keratitis and trauma. Tectonic/reconstructive: To preserve corneal anatomy and integrity in patients with stromal thinning and descemetoceles, or to reconstruct the anatomy of the eye, e.g. after corneal perforation. Therapeutic: To remove inflamed corneal tissue unresponsive to treatment by antibiotics or anti-virals. Cosmetic: To improve the appearance of patients with corneal scars that have given a whitish or opaque hue to the cornea.
In the Borexino Counting Test Facility, a 14C/12C ratio of 1.94×10−18 was determined; probable reactions responsible for varied levels of 14C in different petroleum reservoirs, and the lower 14C levels in methane, have been discussed by Bonvicini et al.
=== Iraqi population === Since 2001, medical personnel working for the Iraqi state health service controlled by Saddam Hussein at the Basra hospital in southern Iraq have reported a sharp increase in the incidence of child leukemia and genetic malformation among babies born in the decade following the Gulf War. Iraqi doctors attributed these malformations to possible long-term effects of DU, an opinion that was echoed by several newspapers. In 2004, Iraq had the highest mortality rate due to leukemia of any country. In 2003, the Royal Society called for Western militaries to disclose where and how much DU they had used in Iraq so that rigorous, and hopefully conclusive, studies could be undertaken in affected areas. The International Coalition to Ban Uranium Weapons (ICBUW) likewise urged that an epidemiological study be made in the Basra region, as requested by Iraqi doctors, but no peer-reviewed study has yet been undertaken in Basra. A medical survey, "Cancer, Infant Mortality and Birth Sex Ratio in Fallujah, Iraq 2005–2009" published in July 2010, states that the "...increases in cancer and birth defects...are alarmingly high" and that infant mortality 2009/2010 has reached 13.6%. The group compares the dramatic increase, five years after wartime exposure in 2004, with the lymphoma that Italian peacekeepers developed after the Balkan wars and the increased cancer risk in certain parts of Sweden because of the Chernobyl fallout.
IATA estimates that over a billion lithium metal and lithium-ion cells are flown each year. Some kinds of lithium batteries may be prohibited aboard aircraft because of the fire hazard. Some postal administrations restrict air shipping (including EMS) of lithium and lithium-ion batteries, either separately or installed in equipment.
Sources: en.wikipedia.org
=== Crack tip plastic zone === In theory the stress at the crack tip where the radius is nearly zero, would tend to infinity. This would be considered a stress singularity, which is not possible in real-world applications. For this reason, in numerical studies in the field of fracture mechanics, it is often appropriate to represent cracks as round tipped notches, with a geometry dependent region of stress concentration replacing the crack-tip singularity. In actuality, the stress concentration at the tip of a crack within real materials has been found to have a finite value but larger than the nominal stress applied to the specimen. Nevertheless, there must be some sort of mechanism or property of the material that prevents such a crack from propagating spontaneously. The assumption is, the plastic deformation at the crack tip effectively blunts the crack tip. This deformation depends primarily on the applied stress in the applicable direction (in most cases, this is the y-direction of a regular Cartesian coordinate system), the crack length, and the geometry of the specimen. To estimate how this plastic deformation zone extended from the crack tip, Irwin equated the yield strength of the material to the far-field stresses of the y-direction along the crack (x direction) and solved for the effective radius. From this relationship, and assuming that the crack is loaded to the critical stress intensity factor, Irwin developed the following expression for the idealized radius of the zone of plastic deformation at the crack tip:
==== Opioids ==== The use of opioids is controversial. As of 2015, no opioid is approved for use in this condition by the FDA. A 2016 Cochrane review concluded that there is no good evidence to support or refute the suggestion that oxycodone, alone or in combination with naloxone, reduces pain in fibromyalgia. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in 2014 stated that there was a lack of evidence for opioids for most people. The Association of the Scientific Medical Societies in Germany in 2012 made no recommendation either for or against the use of weak opioids because of the limited amount of scientific research addressing their use in the treatment of fibromyalgia. They strongly advise against using strong opioids. The Canadian Pain Society in 2012 said that opioids, starting with a weak opioid like tramadol, can be tried but only for people with moderate to severe pain that is not well-controlled by non-opioid painkillers. They discourage the use of strong opioids and only recommend using them while they continue to provide improved pain and functioning. Healthcare providers should monitor people on opioids for ongoing effectiveness, side effects, and possible unwanted drug behaviors. A 2015 review found fair evidence to support tramadol use if other medications do not work. A 2018 review found little evidence to support the combination of paracetamol (acetaminophen) and tramadol over a single medication.
is independent of strain rate. Such fluids are called Newtonian. Gases, water, and many common liquids can be considered Newtonian in ordinary conditions and contexts. However, there are many non-Newtonian fluids that significantly deviate from this behavior. For example:
Renwick (1839), mechanical engineer, patent expert Oliver Wolcott Gibbs (1841), chemist, president of the National Academy of Sciences and the American Association for the Advancement of Science Robert Ogden Doremus* (1842), chemist and physician Cornelius Rea Agnew (1849), physician who helped founding the Manhattan Eye, Ear and Throat Hospital Henry Carrington Bolton (1862), chemist and bibliographer of science Stuyvesant Fish Morris (1863), physician, nephew of Hamilton Fish '27 Rudolph August Witthaus (1867), toxicologist Frederick Remsen Hutton (1873), engineer, president of the American Society of Mechanical Engineers Sylvanus Albert Reed (1874), aerospace engineer who developed the modern metal aircraft propeller, which won the 1925 Collier Trophy William Hallock (1879), physicist, professor at Columbia University William Barclay Parsons (1879), chief engineer of the first line of the New York City Subway system, founder of multinational engineering firm Parsons Brinckerhoff Michael I. Pupin (1879), physicist, winner of the Pulitzer Prize for biography Henry Crampton (1893), evolutionary biologist Harold Jacoby (1894), astronomer and professor at Columbia University John Duer Irving (1896), geologist, professor at Sheffield Scientific School of Yale University Richard Weil (1896), physician, professor at Weill Cornell Medicine, son-in-law of Isidor Straus Hans Zinsser (1899), physician, bacteriologist, prolific author Marston T.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.